Genfit S.A. (Nasdaq + Euronext: GNFT – ISIN: FR0004163111)

https://www.genfit.com

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions. Its R&D is focused on three franchises: cholestatic diseases, Acute on Chronic Liver Failure (ACLF) and NASH diagnostics. In its cholestatic diseases franchise, ELATIVE™, a Phase 3 global trial evaluating elafibranor1 in patients with Primary Biliary Cholangitis (PBC) is well underway following a successful Phase 2 clinical trial. Topline data is expected to be announced in the second quarter 2023. In 2021, GENFIT signed an exclusive licensing agreement with IPSEN to develop, manufacture and commercialize elafibranor in PBC and other indications.2 GENFIT is also developing GNS5611 in cholangiocarcinoma following the acquisition of exclusive rights in this indication from Genoscience Pharma in 20213. In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated in 2021, and GENFIT further expanded its ACLF pipeline in 2022 via the acquisition of Swiss-based clinical-stage company Versantis, with a Phase 2 ready program evaluating liposomes technology and a preclinical stage small molecule. As part of its diagnostic solutions franchise, the Company entered into an agreement with Labcorp in 2021 to commercialize NASHnext®, powered by GENFIT’s proprietary diagnostic technology NIS4® in identifying at-risk NASH. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital. *

	Start	0199-01-01 established
	Group	Genfit (Group)
	Industry	elafibranor (GFT505)
	Industry 2	drug development
	Person	Mouney, Jean-François (Genfit 201909– Board Chairman before 1999–201909 CEO + Co-Founder)

	Region	Loos (Loos-lez-Lille)
	Country	France
	Street	885 Avenue Eugène Avinée Parc Eurosanté
	City	59120 Loos
	Tel	+33-3-2016-4000
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2022-01-01)
	Currency	EUR
	Annual sales	85,579,000 (income, total, consolidated (2021) 2021-12-31)
	Profit	67,259,000 (2021-12-31)
	Cash	258,756,000 (2021-12-31)

		* Document for »About Section«: Genfit S.A.. (9/19/22). "Press Release: Genfit to Acquire Clinical-stage Biopharmaceutical Company Versantis, Expanding Its Portfolio in Liver Diseases". Lille & Cambridge, MA.

		Record changed: 2024-06-13